As we head into the fall and winter months, there will likely be an increase in the number of COVID-19 cases around the country. While vaccination continues to provide the best protection, COVID-19 therapies are widely available to help treat eligible people who do get sick and are at risk of developing severe disease. Antiviral treatments for patients at risk for COVID-19 reduces their risk of hospitalization and death.
The antiviral Paxlovid (ritonavir-boosted nirmatrelvir) along with Veklury (remdesivir) are they preferred treatments for eligible adult and pediatric patients with positive COVID-19 test results and who are at risk for progression to severe COVID-19. COVID-19 therapeutics should be considered for any COVID-19 patient who meets the eligibility criteria.
This information sheet summarizes current information about Paxlovid and offers resources about other COVID-19 therapeutics. In addition, a study was done to identify the efficacy of Paxlovid among elderly patients with co-morbidities. The study identified that Paxlovid significantly reduced COVID-19 hospitalizations and deaths.